Stabilize and Standardize RNA Blood Samples from the Start for Accurate Clinical Trial Immune Monitoring

Learn why standardized sample collection is critical to capture the full range of immune repertoire biomarkers.

Key Takeaways:

• Accurate biomarker measurement in clinical trials depends on standardized sample collection; variability introduced at the draw can obscure real biological signal downstream.
• PAXgene® tubes set draw volume at 2.5 mL, normalizing whole blood volumes allowing natural variation of T- and B-cell populations in response to treatment and enabling direct comparison across patient samples and cohorts.
• Immediate RNA stabilization upon collection preserves the biological state of the sample, reducing pre-analytical variability prior to AIRRseq analys
• Consistent collection and storage conditions enable researchers to distinguish true shifts in immune repertoire diversity from changes driven by differences in collection and storage variables.

Why Sample Standardization Matters in Clinical Trials

Clinical trials depend on reliable biomarker data. Whether the goal is evaluating disease state, tracking therapeutic response, or identifying predictors of outcome, the quality of that data starts well before any sequencing run. It starts at the moment of patient blood collection.

The adaptive immune system is a rich source of biomarkers for clinical research. Circulating T cells and B cells carry information both in their diversity, captured through immune repertoire sequencing, and in their absolute clone numbers and BCR isotypes, which can shift meaningfully in response to disease or treatment. To measure these signals accurately, and to compare them reliably across patients, time points, and collection sites, researchers need a sample collection method that introduces as little variability as possible.

PAXgene® Blood RNA tubes (IVD) provide a validated approach to standardizing blood collection that enables robust, reliable studies of the immune response in clinical trials.

The Problem with Inconsistent Blood Collection Methods

In a multi-site clinical trial, variability in blood collection can creep in from several directions: differences in draw volume, inconsistent handling times before stabilization, or RNA degradation during transport. For immune repertoire profiling specifically, these inconsistencies can obscure real biological signal.

If the amount of blood drawn varies across samples, apparent differences in cell number or clonal abundance may reflect collection differences rather than true biological change. Separating those two sources of variation is critical for drawing accurate conclusions in a clinical study.

What PAXgene Blood RNA Tubes Offer

PAXgene Blood RNA tubes are designed for stabilizing total RNA from whole blood, including RNA from white blood cells (WBCs). Several features make them well-suited to clinical immune repertoire studies.

1. Fixed draw volume: Each PAXgene tube collects exactly 2.5 mL of blood. This fixed volume is one of the most consequential features for clinical research, because it normalizes the blood volume captured at every draw. When blood volume is held constant, researchers can make direct comparisons of absolute T and B cell counts between samples, across patients, and across time points within the same patient.
2. Immediate RNA stabilization: Upon collection, PAXgene tubes immediately stabilize RNA by inhibiting ex vivo changes in gene expression. This preserves the biological state of the sample at the moment of collection and prevents RNA degradation during transport or processing delays, a common source of pre-analytical variability in clinical settings.
3. Simplified workflow: PAXgene tubes do not require a red blood cell lysis step prior to RNA extraction, which simplifies the processing workflow and reduces potential for cell loss or inadvertent immune cell activation that can occur with additional handling steps.

The result is a consistent, high-quality RNA input well-suited for downstream immune repertoire sequencing, including amplification and sequencing of the immune system’s T and B cell receptor genes.

Clone Count as a Biomarker: Why Volume Standardization Changes the Analysis

One aspect of PAXgene tubes that is especially relevant for clinical immune research often receives less attention than RNA quality: the fixed draw volume enables clone count itself to be treated as a biomarker.

In studies of immune reconstitution, for example following hematopoietic stem cell transplantation or lymphocyte-depleting therapy in autoimmune disease, changes in the repertoire of circulating clones serves as a meaningful clinical signal. Tracking that signal requires knowing not just what receptors are present, but how many clones are contributing to the sample.

Because PAXgene tubes fix the draw volume at 2.5 mL, researchers can normalize clone counts to blood volume and make those comparisons with confidence. This also allows for a more nuanced interpretation of diversity metrics.

PAXgene-collected samples capture patient-specific diversity of both B cells and T cells within each draw, providing a representative snapshot of the immune repertoire at that time point. That consistency across samples is foundational to longitudinal clinical studies.

PAXgene Tubes and iRepertoire’s Sequencing Workflow

iRepertoire’s immune repertoire sequencing platform is built for depth and reproducibility. PAXgene-collected blood RNA is compatible with our workflow and supports multi-chain capture of both T cell receptor (TCR) and B cell receptor (BCR) sequences, enabling comprehensive profiling of the adaptive immune response from a single standardized input.

For researchers designing clinical studies, pairing PAXgene tubes with our sequencing approach means that variability introduced at the collection step is minimized before the sample ever reaches the sequencer. For additional guidance on clinical sample collection, see our blood collection and sample considerations resource.

Plan Your Clinical Study with Confidence

Reliable immune biomarker data in clinical trials begins with a reliable sample. PAXgene Blood RNA tubes address the most common sources of pre-analytical variability in blood-based immune profiling: draw volume, RNA stability, and workflow consistency. By standardizing from the point of collection, researchers can measure both T and B cell diversity and cell number as meaningful, comparable outputs across their study cohort.

If you are designing a clinical study that incorporates immune repertoire profiling, our team is available to help you think through every step, from sample collection strategy through sequencing and data analysis. Download our experiment planning eBook to get started, or contact us to discuss your study design with our scientific team.